Lacerta Therapeutics Appoints Min Wang, PhD, JD and Marc Wolff to Its Board of Directors
UF startup and UF Innovate | Accelerate at Sid Martin Biotech graduate Lacerta Therapeutics, Inc., a gene therapy company dedicated to the discovery and development of AAV-based gene therapies, appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors.
Dr. Min Wang has over 20 years of experience in the biotech space where she has operated as a business and legal advisor to the board and senior management at private and publicly traded companies through different phases of their organizational lifecycle. Dr. Wang most recently served as COO at Monte Rosa Therapeutics, where she held broad management responsibilities for key corporate functions. Previously, Dr. Wang served as COO of BlueRock Therapeutics through its acquisition by Bayer in 2019.
Marc Wolff brings more than 23 years of experience in the life sciences industry in various management and finance leadership roles. Mr. Wolff is currently CEO at Calviri, a fully integrated healthcare company whose mission is to provide a broad spectrum of therapeutic vaccines and early diagnostics that prevent and treat cancer. Prior to joining Calviri, Mr. Wolff served as COO and CFO of Aldevron where he played a key role in scaling the company through exponential growth, enabling Aldevron’s clients to access essential GMP materials for their novel applications in gene and cell therapy.
Learn more about Lacerta Therapeutics Appoints Min Wang, PhD, JD and Marc Wolff to Its Board of Directors.